Cargando…
Pathologic responses and surgical outcomes after neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma
BACKGROUND: Currently, the role of immunotherapy in neoadjuvant setting for patients with locally advanced esophageal squamous cell carcinoma (ESCC) is gradually attracting attention. Few studies compared the efficacy of neoadjuvant immunochemotherapy (NICT) and neoadjuvant chemoradiotherapy (NCRT)....
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713810/ https://www.ncbi.nlm.nih.gov/pubmed/36466925 http://dx.doi.org/10.3389/fimmu.2022.1052542 |
_version_ | 1784842092571262976 |
---|---|
author | Xu, Lei Wei, Xiu-feng Li, Can-jun Yang, Zhao-yang Yu, Yong-kui Li, Hao-miao Xie, Hou-nai Yang, Ya-fan Jing, Wei-wei Wang, Zhen Kang, Xiao-zheng Zhang, Rui-xiang Qin, Jian-jun Xue, Li-yan Bi, Nan Chen, Xian-kai Li, Yin |
author_facet | Xu, Lei Wei, Xiu-feng Li, Can-jun Yang, Zhao-yang Yu, Yong-kui Li, Hao-miao Xie, Hou-nai Yang, Ya-fan Jing, Wei-wei Wang, Zhen Kang, Xiao-zheng Zhang, Rui-xiang Qin, Jian-jun Xue, Li-yan Bi, Nan Chen, Xian-kai Li, Yin |
author_sort | Xu, Lei |
collection | PubMed |
description | BACKGROUND: Currently, the role of immunotherapy in neoadjuvant setting for patients with locally advanced esophageal squamous cell carcinoma (ESCC) is gradually attracting attention. Few studies compared the efficacy of neoadjuvant immunochemotherapy (NICT) and neoadjuvant chemoradiotherapy (NCRT). Our study aimed to compare treatment response and postoperative complications after NICT followed by surgery with that after conventional NCRT in patients with locally advanced ESCC. METHODS: Of 468 patients with locally advanced ESCC, 154 received conventional NCRT, whereas 314 received NICT. Treatment response, postoperative complications and mortality between two groups were compared. Pathological response of primary tumor was evaluated using the Mandard tumor regression grade (TRG) scoring system. Pathological complete response (pCR) of metastatic lymph nodes (LNs) was defined as no viable tumor cell within all resected metastatic LNs. According to regression directionality, tumor regression pattern was summarized into four categories: type I, regression toward the lumen; type II, regression toward the invasive front; type III, concentric regression; and type IV, scattered regression. Inverse probability propensity score weighting was performed to minimize the influence of confounding factors. RESULTS: After adjusting for baseline characteristics, the R0 resection rates (90.9% vs. 89.0%, P=0.302) and pCR (ypT0N0) rates (29.8% vs. 34.0%, P=0.167) were comparable between two groups. Patients receiving NCRT showed lower TRG score (P<0.001) and higher major pathological response (MPR) rate (64.7% vs. 53.6%, P=0.001) compared to those receiving NICT. However, NICT brought a higher pCR rate of metastatic LNs than conventional NCRT (53.9% vs. 37.1%, P<0.001). The rates of type I/II/III/IV regression patterns were 44.6%, 6.8%, 11.4% and 37.1% in the NICT group, 16.9%, 8.2%, 18.3% and 56.6% in the NCRT group, indicating a significant difference (P<0.001). Moreover, there were no significant differences in the incidence of total postoperative complications (35.8% vs. 39.9%, P=0.189) and 30-d mortality (0.0% vs. 1.1%, P=0.062). CONCLUSION: For patients with locally advanced ESCC, NICT showed a R0 resection rate and pCR (ypT0N0) rate comparable to conventional NCRT, without increased incidence of postoperative complications and mortality. Notablely, NICT followed by surgery might bring a promising treatment response of metastatic LNs. |
format | Online Article Text |
id | pubmed-9713810 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97138102022-12-02 Pathologic responses and surgical outcomes after neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma Xu, Lei Wei, Xiu-feng Li, Can-jun Yang, Zhao-yang Yu, Yong-kui Li, Hao-miao Xie, Hou-nai Yang, Ya-fan Jing, Wei-wei Wang, Zhen Kang, Xiao-zheng Zhang, Rui-xiang Qin, Jian-jun Xue, Li-yan Bi, Nan Chen, Xian-kai Li, Yin Front Immunol Immunology BACKGROUND: Currently, the role of immunotherapy in neoadjuvant setting for patients with locally advanced esophageal squamous cell carcinoma (ESCC) is gradually attracting attention. Few studies compared the efficacy of neoadjuvant immunochemotherapy (NICT) and neoadjuvant chemoradiotherapy (NCRT). Our study aimed to compare treatment response and postoperative complications after NICT followed by surgery with that after conventional NCRT in patients with locally advanced ESCC. METHODS: Of 468 patients with locally advanced ESCC, 154 received conventional NCRT, whereas 314 received NICT. Treatment response, postoperative complications and mortality between two groups were compared. Pathological response of primary tumor was evaluated using the Mandard tumor regression grade (TRG) scoring system. Pathological complete response (pCR) of metastatic lymph nodes (LNs) was defined as no viable tumor cell within all resected metastatic LNs. According to regression directionality, tumor regression pattern was summarized into four categories: type I, regression toward the lumen; type II, regression toward the invasive front; type III, concentric regression; and type IV, scattered regression. Inverse probability propensity score weighting was performed to minimize the influence of confounding factors. RESULTS: After adjusting for baseline characteristics, the R0 resection rates (90.9% vs. 89.0%, P=0.302) and pCR (ypT0N0) rates (29.8% vs. 34.0%, P=0.167) were comparable between two groups. Patients receiving NCRT showed lower TRG score (P<0.001) and higher major pathological response (MPR) rate (64.7% vs. 53.6%, P=0.001) compared to those receiving NICT. However, NICT brought a higher pCR rate of metastatic LNs than conventional NCRT (53.9% vs. 37.1%, P<0.001). The rates of type I/II/III/IV regression patterns were 44.6%, 6.8%, 11.4% and 37.1% in the NICT group, 16.9%, 8.2%, 18.3% and 56.6% in the NCRT group, indicating a significant difference (P<0.001). Moreover, there were no significant differences in the incidence of total postoperative complications (35.8% vs. 39.9%, P=0.189) and 30-d mortality (0.0% vs. 1.1%, P=0.062). CONCLUSION: For patients with locally advanced ESCC, NICT showed a R0 resection rate and pCR (ypT0N0) rate comparable to conventional NCRT, without increased incidence of postoperative complications and mortality. Notablely, NICT followed by surgery might bring a promising treatment response of metastatic LNs. Frontiers Media S.A. 2022-11-17 /pmc/articles/PMC9713810/ /pubmed/36466925 http://dx.doi.org/10.3389/fimmu.2022.1052542 Text en Copyright © 2022 Xu, Wei, Li, Yang, Yu, Li, Xie, Yang, Jing, Wang, Kang, Zhang, Qin, Xue, Bi, Chen and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Xu, Lei Wei, Xiu-feng Li, Can-jun Yang, Zhao-yang Yu, Yong-kui Li, Hao-miao Xie, Hou-nai Yang, Ya-fan Jing, Wei-wei Wang, Zhen Kang, Xiao-zheng Zhang, Rui-xiang Qin, Jian-jun Xue, Li-yan Bi, Nan Chen, Xian-kai Li, Yin Pathologic responses and surgical outcomes after neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma |
title | Pathologic responses and surgical outcomes after neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma |
title_full | Pathologic responses and surgical outcomes after neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma |
title_fullStr | Pathologic responses and surgical outcomes after neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma |
title_full_unstemmed | Pathologic responses and surgical outcomes after neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma |
title_short | Pathologic responses and surgical outcomes after neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma |
title_sort | pathologic responses and surgical outcomes after neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713810/ https://www.ncbi.nlm.nih.gov/pubmed/36466925 http://dx.doi.org/10.3389/fimmu.2022.1052542 |
work_keys_str_mv | AT xulei pathologicresponsesandsurgicaloutcomesafterneoadjuvantimmunochemotherapyversusneoadjuvantchemoradiotherapyinpatientswithlocallyadvancedesophagealsquamouscellcarcinoma AT weixiufeng pathologicresponsesandsurgicaloutcomesafterneoadjuvantimmunochemotherapyversusneoadjuvantchemoradiotherapyinpatientswithlocallyadvancedesophagealsquamouscellcarcinoma AT licanjun pathologicresponsesandsurgicaloutcomesafterneoadjuvantimmunochemotherapyversusneoadjuvantchemoradiotherapyinpatientswithlocallyadvancedesophagealsquamouscellcarcinoma AT yangzhaoyang pathologicresponsesandsurgicaloutcomesafterneoadjuvantimmunochemotherapyversusneoadjuvantchemoradiotherapyinpatientswithlocallyadvancedesophagealsquamouscellcarcinoma AT yuyongkui pathologicresponsesandsurgicaloutcomesafterneoadjuvantimmunochemotherapyversusneoadjuvantchemoradiotherapyinpatientswithlocallyadvancedesophagealsquamouscellcarcinoma AT lihaomiao pathologicresponsesandsurgicaloutcomesafterneoadjuvantimmunochemotherapyversusneoadjuvantchemoradiotherapyinpatientswithlocallyadvancedesophagealsquamouscellcarcinoma AT xiehounai pathologicresponsesandsurgicaloutcomesafterneoadjuvantimmunochemotherapyversusneoadjuvantchemoradiotherapyinpatientswithlocallyadvancedesophagealsquamouscellcarcinoma AT yangyafan pathologicresponsesandsurgicaloutcomesafterneoadjuvantimmunochemotherapyversusneoadjuvantchemoradiotherapyinpatientswithlocallyadvancedesophagealsquamouscellcarcinoma AT jingweiwei pathologicresponsesandsurgicaloutcomesafterneoadjuvantimmunochemotherapyversusneoadjuvantchemoradiotherapyinpatientswithlocallyadvancedesophagealsquamouscellcarcinoma AT wangzhen pathologicresponsesandsurgicaloutcomesafterneoadjuvantimmunochemotherapyversusneoadjuvantchemoradiotherapyinpatientswithlocallyadvancedesophagealsquamouscellcarcinoma AT kangxiaozheng pathologicresponsesandsurgicaloutcomesafterneoadjuvantimmunochemotherapyversusneoadjuvantchemoradiotherapyinpatientswithlocallyadvancedesophagealsquamouscellcarcinoma AT zhangruixiang pathologicresponsesandsurgicaloutcomesafterneoadjuvantimmunochemotherapyversusneoadjuvantchemoradiotherapyinpatientswithlocallyadvancedesophagealsquamouscellcarcinoma AT qinjianjun pathologicresponsesandsurgicaloutcomesafterneoadjuvantimmunochemotherapyversusneoadjuvantchemoradiotherapyinpatientswithlocallyadvancedesophagealsquamouscellcarcinoma AT xueliyan pathologicresponsesandsurgicaloutcomesafterneoadjuvantimmunochemotherapyversusneoadjuvantchemoradiotherapyinpatientswithlocallyadvancedesophagealsquamouscellcarcinoma AT binan pathologicresponsesandsurgicaloutcomesafterneoadjuvantimmunochemotherapyversusneoadjuvantchemoradiotherapyinpatientswithlocallyadvancedesophagealsquamouscellcarcinoma AT chenxiankai pathologicresponsesandsurgicaloutcomesafterneoadjuvantimmunochemotherapyversusneoadjuvantchemoradiotherapyinpatientswithlocallyadvancedesophagealsquamouscellcarcinoma AT liyin pathologicresponsesandsurgicaloutcomesafterneoadjuvantimmunochemotherapyversusneoadjuvantchemoradiotherapyinpatientswithlocallyadvancedesophagealsquamouscellcarcinoma |